

<p align="center"><b>NATIONAL PHASE UTILITY APPLICATION</b></p> <p align="center"><b>Transmittal to the (DO/EO/US) Under 35 USC 371</b></p>	<p>Attorney Docket No.: VTOB.138NP  First Named Inventor: Mark Conkling  Int'l Application No.: PCT/US2004/016958  Int'l Filing Date: May 27, 2004  Priority Date Claimed: June 4, 2003  Title: METHOD OF REDUCING THE HARMFUL EFFECTS OF  ORALLY OR TRANSDERMALLY DELIVERED  NICOTINE  Express Mail Label No.: EV 468060224 US</p>
<p><b>Direct all correspondence to Customer No.: 20995</b> <span style="float: right;">Date: December 2, 2005 Page 1 of 3</span></p>	

Mail Stop PCT  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria VA 22313-1450

The following enclosures are transmitted herewith to be filed in the patent application of:

Inventors:

1. Mark Conkling

**APPLICATION ELEMENTS:**

- (X) This is a FIRST submission of items concerning a filing under 35 U.S.C. § 371.
- (X) A copy of the International Application as filed (35 U.S.C. § 371(c)(2)) is not required, as the application was filed in the U.S. Receiving Office.
- (X) An English translation of the International Application as filed is not required.
- (X) Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3)) have not been and will not be made.

**OTHER APPLICATION PARTS:**

- (X) Preliminary Amendment in 8 pages.
- (X) Sequence Submission Statement in 2 pages, and
- (X) Sequence Listing in CRF
- (X) Sequence Listing on paper in 1 page
- (X) Return prepaid postcard.
- (x) Foreign Search Report

10/559113

<b>NATIONAL PHASE UTILITY APPLICATION</b> <b>Transmittal to the (DO/EO/US)</b> <b>Under 35 USC 371</b>	Attorney Docket No.: VTOB.138NP First Named Inventor: Mark Conikling Int'l Application No.: PCT/US2004/016958 Int'l Filing Date: May 27, 2004 Priority Date Claimed: June 4, 2003 Title: METHOD OF REDUCING THE HARMFUL EFFECTS OF ORALLY OR TRANSDERMALLY DELIVERED NICOTINE Express Mail Label No.: EV 468060224 US
<b>Direct all correspondence to Customer No.: 20995</b>	
Date: December 2, 2005 Page 2 of 3	

**FILING FEES:**

FEE CALCULATION			
FEE TYPE & DETERMINATION		LARGE FEE	TOTAL
Basic Filing Fee under 1.492(a)		1631 (\$300)	\$300
Search Fee under 1.492(b) (enter one in TOTAL column)			
(1) USPTO was ISA/IPEA & claims satisfy Art. 33 (1)-(4)		1640 (\$0)	\$500
(2) USPTO was the ISA (noncompliant claims)		1641 (\$100)	
(3) Foreign Search Report Enclosed		1642 (\$400)	
(4) No Search Report Enclosed		1632 (\$500)	
Examination Fee under 1.492(c) (enter one in TOTAL column)			
(1) USPTO was ISA/IPEA & claims satisfy Art. 33 (1)-(4)		1643 (\$0)	\$0
(2) Non US IPEA or Noncompliant Claims		1633 (\$200)	
Excess Claims	48 - 20 = 28	1615 (\$50)	28 x 50 = \$1,400
Excess Ind. Claims	8 - 3 = 5	1614 (\$200)	5 x 200 = \$1,000
Multiple Dep. Claim		1616 (\$360)	\$360
Application Size Fee	0 - 100 = 0	1681 (\$250)	0 x 250 = \$0
Late English Translation		1618 (\$130)	\$0
Assignment		8021 (\$40)	0 x 40 = \$0
		<b>TOTAL FEE DUE</b>	<b>\$3,560</b>
<b>TOTAL FEE PAID (If Different Than Fee Due)</b>			<b>\$N/A</b>

(X) A check in the amount of \$3,560 to cover the Total Fee Due is enclosed.

10516 RECEIVED U.S. DEC 2005

**NATIONAL PHASE  
UTILITY APPLICATION**

**Transmittal to the (DO/EO/US)  
Under 35 USC 371**


Attorney Docket No.: VTOB.138NP  
First Named Inventor: Mark Conkling  
Int'l Application No.: PCT/US2004/016958  
Int'l Filing Date: May 27, 2004  
Priority Date Claimed: June 4, 2003  
Title: METHOD OF REDUCING THE HARMFUL EFFECTS OF  
ORALLY OR TRANSDERMALLY DELIVERED  
NICOTINE  
Express Mail Label No.: EV 468060224 US

**Direct all correspondence to Customer No.: 20995**

Date: December 2, 2005

Page 3 of 3

The Commissioner is hereby authorized to charge any additional fees which may be required, now or in the future, or credit any overpayment to Account No. 11-1410.

  
\_\_\_\_\_  
Neil S. Bartfeld, Ph.D.  
Registration No. 39,901  
Agent of Record  
Customer No. 20,995  
(619) 235-8550

2160337  
120205